The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes

Bin Fu, Chi Young Ok, Maitrayee Goswami, Wei Xei, Jesse M. Jaso, Tariq Muzzafar, Carlos Bueso-Ramos, Srdan Verstovsek, Guillermo Garcia-Manero, L. Jeffrey Medeiros, Sa A. Wang

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

The presence of moderate to severe bone marrow (BM) fibrosis has been shown to be an adverse feature in patients with primary myelodysplastic syndromes (MDS). However, the clinical importance of BM fibrosis is not clear in therapy-related MDS. We retrieved all therapy-related MDS (t-MDS) cases (n = 266) diagnosed at our hospital over a 10-year period (2003-2012). Reticulin and trichrome stains were performed in cases in which BM fibrosis was suspected on initial evaluation of hematoxylin and eosin-stained slide. BM fibrosis was graded according to European consensus guidelines, and a score of MF2/MF3 was defined as moderate/severe fibrosis. Moderate/severe BM fibrosis was found in 47 (17 %) patients. Compared to 219 patients with no/mild BM fibrosis, the patients with moderate/severe fibrosis presented with severer thrombocytopenia (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and neutropenia, transfusion requirements, and similar incidences of hepatosplenomegaly and constitutional symptoms. Histological examination revealed a comparable BM cellularity and BM blast percentage, but markedly increased megakaryocytes (p < 0.001) in the fibrotic group. Although the risk distribution of cytogenetic data was similar according to the New Comprehensive Cytogenetic Scoring criteria, -5 and -17 were more frequently observed in t-MDS with moderate/severe BM fibrosis (p = 0.031 and p = 0.043, respectively). With a median follow-up of 11.5 months, patients with moderate/severe BM fibrosis showed a similar risk of acute myeloid leukemia transformation and a comparable overall survival in univariate and multivariate analyses. Moderate/severe BM fibrosis in patients with t-MDS is associated with certain clinicopathological and genetic features. However, unlike the situation in patients with primary MDS, moderate/severe BM fibrosis does not add additional risk to patients with therapy-related MDS.

Original languageEnglish (US)
Pages (from-to)1335-1343
Number of pages9
JournalAnnals of Hematology
Volume92
Issue number10
DOIs
StatePublished - Oct 2013

Keywords

  • AML transformation
  • Bone marrow fibrosis
  • Cytogenetics
  • Overall survival
  • Therapy-related myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Fu, B., Ok, C. Y., Goswami, M., Xei, W., Jaso, J. M., Muzzafar, T., Bueso-Ramos, C., Verstovsek, S., Garcia-Manero, G., Medeiros, L. J., & Wang, S. A. (2013). The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Annals of Hematology, 92(10), 1335-1343. https://doi.org/10.1007/s00277-013-1776-3